Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target
H Zhang, JM Penninger, Y Li, N Zhong… - Intensive care medicine, 2020 - Springer
A novel infectious disease, caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), was detected in Wuhan, China, in December 2019. The disease (COVID-19) …
(SARS-CoV-2), was detected in Wuhan, China, in December 2019. The disease (COVID-19) …
Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant
M Pachetti, B Marini, F Benedetti, F Giudici… - Journal of translational …, 2020 - Springer
Background SARS-CoV-2 is a RNA coronavirus responsible for the pandemic of the Severe
Acute Respiratory Syndrome (COVID-19). RNA viruses are characterized by a high mutation …
Acute Respiratory Syndrome (COVID-19). RNA viruses are characterized by a high mutation …
[HTML][HTML] SARS-CoV-2: an emerging coronavirus that causes a global threat
J Zheng - International journal of biological sciences, 2020 - ncbi.nlm.nih.gov
An ongoing outbreak of pneumonia caused by a novel coronavirus, currently designated as
the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), was reported recently …
the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), was reported recently …
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies
The emergence and rapid spread of coronavirus disease 2019 (COVID-19), caused by
severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a potentially fatal disease …
severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a potentially fatal disease …
COVID-19 and the heart
A Akhmerov, E Marbán - Circulation research, 2020 - Am Heart Assoc
Infection with the severe acute respiratory syndrome novel coronavirus produces a clinical
syndrome known as 2019 novel coronavirus disease (COVID-19). When severe, COVID-19 …
syndrome known as 2019 novel coronavirus disease (COVID-19). When severe, COVID-19 …
[HTML][HTML] An overview of COVID-19
Pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection emerged in Wuhan City, Hubei Province, China in December 2019. By Feb. 11 …
infection emerged in Wuhan City, Hubei Province, China in December 2019. By Feb. 11 …
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised …
Background Effective antiviral therapy is important for tackling the coronavirus disease 2019
(COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b …
(COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b …
Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics
D Gurwitz - Drug development research, 2020 - Wiley Online Library
At the time of writing this commentary (February 2020), the coronavirus COVID‐19 epidemic
has already resulted in more fatalities compared with the SARS and MERS coronavirus …
has already resulted in more fatalities compared with the SARS and MERS coronavirus …
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
A new coronavirus SARS-CoV-2, also called novel coronavirus 2019 (2019-nCoV), started
to circulate among humans around December 2019, and it is now widespread as a global …
to circulate among humans around December 2019, and it is now widespread as a global …
[HTML][HTML] C-reactive protein levels in the early stage of COVID-19
L Wang - Medecine et maladies infectieuses, 2020 - Elsevier
Background COVID-19 is a new infectious disease, for which there is currently no treatment.
It is therefore necessary to explore biomarkers to determine the extent of lung lesions and …
It is therefore necessary to explore biomarkers to determine the extent of lung lesions and …